{
  "id": 18502676,
  "title": "Guggenheim raises Septerna stock price target to $65 on pipeline progress",
  "url": "https://urgent.news/2026/11/06/guggenheim-raises-septerna-stock-price-target-to-65-on-pipeline",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T13:08:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-septerna-stock-price-target-to-65-on-pipeline-progress-93CH-5007973"
  },
  "original_language": "en",
  "account": "Investing.com reports that Guggenheim has increased its price target on Septerna Inc shares to $65 from $51, while maintaining a Buy rating. The firm has raised its probability of success for the company's oral small molecule PTH replacement SEP-479 to 50% from 35%. Additionally, Guggenheim has incorporated risk-adjusted sales estimates for SEP-204, a Graves' disease treatment, into its model with a 10% probability of success. Septerna's stock has risen 70% year-to-date, surpassing the XBI biotech index's 22% gain and the S&P 500's 7% increase. The company's Graves' disease asset is set to enter the clinic in the first quarter of 2027, ahead of expectations.",
  "summary": null,
  "key_points": [
    "Guggenheim raises Septerna's stock price target to $65 from $51",
    "Increases SEP-479 oral small molecule PTH replacement success probability to 50%",
    "Incorporates risk-adjusted sales estimates for SEP-204 Graves' disease treatment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}